Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH-139: Gamitrinib in Advanced Cancer
NCT04827810Phase 1Suspended
- Sponsor
- Fox Chase Cancer Center
- Start
- Nov 2021
- Primary completion
- Jun 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gamitrinib in lymphoma and solid tumor (advanced stage) (7 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 7 years. Started Nov 2021; status: suspended.
02
Drugs
gamitrinib
03
Conditions
lymphomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04827810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827810.